Which has preferable valuation & earnings, GHRS or LNTH?

Lantheus has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$1.00 N/A Lantheus $1.54B 4.24 $233.56M $4.14 24.21

Is GHRS or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to GH Research's net margin of 0.00%. Lantheus' return on equity of 28.10% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.86% -20.12% Lantheus 17.69% 28.10% 14.35%

Does the media refer more to GHRS or LNTH?

In the previous week, Lantheus had 5 more articles in the media than GH Research. MarketBeat recorded 7 mentions for Lantheus and 2 mentions for GH Research. GH Research's average media sentiment score of 1.61 beat Lantheus' score of 0.81 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GHRS or LQDA more profitable?

Liquidia has a net margin of 30.74% compared to GH Research's net margin of 0.00%. Liquidia's return on equity of 149.65% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.86% -20.12% Liquidia 30.74% 149.65% 36.30%

Does the media favor GHRS or LQDA?

In the previous week, Liquidia had 2 more articles in the media than GH Research. MarketBeat recorded 4 mentions for Liquidia and 2 mentions for GH Research. GH Research's average media sentiment score of 1.61 beat Liquidia's score of 1.04 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Liquidia 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMRX or GHRS?

In the previous week, Amneal Pharmaceuticals had 8 more articles in the media than GH Research. MarketBeat recorded 10 mentions for Amneal Pharmaceuticals and 2 mentions for GH Research. GH Research's average media sentiment score of 1.61 beat Amneal Pharmaceuticals' score of 0.46 indicating that GH Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GH Research 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, GHRS or DFTX?

GH Research is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$1.00 N/A Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A

Is GHRS or DFTX more profitable?

GH Research's return on equity of -20.86% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.86% -20.12% Definium Therapeutics N/A -84.01% -63.66%

Does the media favor GHRS or DFTX?

In the previous week, Definium Therapeutics had 10 more articles in the media than GH Research. MarketBeat recorded 12 mentions for Definium Therapeutics and 2 mentions for GH Research. GH Research's average media sentiment score of 1.61 beat Definium Therapeutics' score of 0.41 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Definium Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, MANE or GHRS?

Veradermics is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A -$70M -$1.90 N/A GH Research N/A N/A -$48.26M -$1.00 N/A

Is MANE or GHRS more profitable?

Veradermics' return on equity of 0.00% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A GH Research N/A -20.86% -20.12%

Does the media refer more to MANE or GHRS?

In the previous week, Veradermics and Veradermics both had 2 articles in the media. GH Research's average media sentiment score of 1.61 beat Veradermics' score of 1.58 indicating that GH Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive GH Research 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

GH Research (GHRS) Competitors

$27.20 -0.08 (-0.29%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$27.12 -0.07 (-0.28%)

As of 09/11/2026 07:30 PM Eastern

Compare

GHRS vs. LNTH, LQDA, AMRX, DFTX, and MANE

Should you buy GH Research stock or one of its competitors? GH Research's main competitors and comparable companies include Lantheus (LNTH), Liquidia (LQDA), Amneal Pharmaceuticals (AMRX), Definium Therapeutics (DFTX), and Veradermics (MANE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GH Research compare to Lantheus?

GH Research (NASDAQ:GHRS) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

GH Research presently has a consensus target price of $45.00, suggesting a potential upside of 65.44%. Lantheus has a consensus target price of $108.11, suggesting a potential upside of 7.84%. Given GH Research's stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Lantheus had 5 more articles in the media than GH Research. MarketBeat recorded 7 mentions for Lantheus and 2 mentions for GH Research. GH Research's average media sentiment score of 1.61 beat Lantheus' score of 0.81 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 17.69% compared to GH Research's net margin of 0.00%. Lantheus' return on equity of 28.10% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
Lantheus	17.69%	28.10%	14.35%

56.9% of GH Research shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lantheus has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Lantheus	$1.54B	4.24	$233.56M	$4.14	24.21

GH Research has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

Summary

Lantheus beats GH Research on 9 of the 15 factors compared between the two stocks.

How does GH Research compare to Liquidia?

GH Research (NASDAQ:GHRS) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Liquidia has a net margin of 30.74% compared to GH Research's net margin of 0.00%. Liquidia's return on equity of 149.65% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
Liquidia	30.74%	149.65%	36.30%

GH Research has higher earnings, but lower revenue than Liquidia. GH Research is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Liquidia	$158.32M	37.73	-$68.92M	$1.37	48.72

GH Research has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

GH Research currently has a consensus price target of $45.00, suggesting a potential upside of 65.44%. Liquidia has a consensus price target of $98.08, suggesting a potential upside of 46.96%. Given GH Research's stronger consensus rating and higher probable upside, equities research analysts plainly believe GH Research is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

56.9% of GH Research shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 25.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Liquidia had 2 more articles in the media than GH Research. MarketBeat recorded 4 mentions for Liquidia and 2 mentions for GH Research. GH Research's average media sentiment score of 1.61 beat Liquidia's score of 1.04 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Liquidia	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Liquidia beats GH Research on 9 of the 16 factors compared between the two stocks.

How does GH Research compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Amneal Pharmaceuticals currently has a consensus target price of $19.57, indicating a potential upside of 15.06%. GH Research has a consensus target price of $45.00, indicating a potential upside of 65.44%. Given GH Research's higher probable upside, analysts clearly believe GH Research is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 41.6% of GH Research shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has a net margin of 5.05% compared to GH Research's net margin of 0.00%. GH Research's return on equity of -20.86% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
GH Research	N/A	-20.86%	-20.12%

Amneal Pharmaceuticals has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, GH Research has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.80	$72.06M	$0.49	34.71
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A

In the previous week, Amneal Pharmaceuticals had 8 more articles in the media than GH Research. MarketBeat recorded 10 mentions for Amneal Pharmaceuticals and 2 mentions for GH Research. GH Research's average media sentiment score of 1.61 beat Amneal Pharmaceuticals' score of 0.46 indicating that GH Research is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GH Research	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Amneal Pharmaceuticals beats GH Research on 8 of the 15 factors compared between the two stocks.

How does GH Research compare to Definium Therapeutics?

GH Research (NASDAQ:GHRS) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

GH Research is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

56.9% of GH Research shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

GH Research has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

GH Research's return on equity of -20.86% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
Definium Therapeutics	N/A	-84.01%	-63.66%

In the previous week, Definium Therapeutics had 10 more articles in the media than GH Research. MarketBeat recorded 12 mentions for Definium Therapeutics and 2 mentions for GH Research. GH Research's average media sentiment score of 1.61 beat Definium Therapeutics' score of 0.41 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Definium Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

GH Research currently has a consensus price target of $45.00, indicating a potential upside of 65.44%. Definium Therapeutics has a consensus price target of $63.00, indicating a potential upside of 62.00%. Given GH Research's higher possible upside, equities research analysts clearly believe GH Research is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

GH Research beats Definium Therapeutics on 8 of the 14 factors compared between the two stocks.

How does GH Research compare to Veradermics?

Veradermics (NYSE:MANE) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

In the previous week, Veradermics and Veradermics both had 2 articles in the media. GH Research's average media sentiment score of 1.61 beat Veradermics' score of 1.58 indicating that GH Research is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
GH Research	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Veradermics currently has a consensus target price of $153.00, suggesting a potential upside of 54.23%. GH Research has a consensus target price of $45.00, suggesting a potential upside of 65.44%. Given GH Research's stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Veradermics is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A

Veradermics' return on equity of 0.00% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
GH Research	N/A	-20.86%	-20.12%

56.9% of GH Research shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

GH Research beats Veradermics on 9 of the 11 factors compared between the two stocks.

Get GH Research News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GHRS vs. The Competition

Export

Metric	GH Research	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.87B	$12.43B	$7.13B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	-27.20	799.75	275.24	25.29
Price / Sales	N/A	763.36	656.02	98.94
Price / Cash	N/A	89.25	77.04	51.44
Price / Book	6.03	10.39	10.33	6.20
Net Income	-$48.26M	$2.85B	$3.50B	$358.50M
7 Day Performance	-3.65%	-3.61%	-3.32%	-2.35%
1 Month Performance	-10.05%	0.86%	-0.41%	-2.77%
1 Year Performance	127.81%	3.47%	19.21%	7.63%

GH Research Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GHRS GH Research	2.6272 of 5 stars	$27.20 -0.3%	$45.00 +65.4%	+117.9%	$1.87B	N/A	N/A	73	Positive News
LNTH Lantheus	3.6328 of 5 stars	$100.53 -0.4%	$108.11 +7.5%	+82.3%	$6.56B	$1.56B	24.28	1,193	News Coverage Positive News Analyst Downgrade
LQDA Liquidia	3.8001 of 5 stars	$67.83 -1.2%	$98.08 +44.6%	+147.2%	$6.06B	$158.32M	49.44	50	Analyst Downgrade
AMRX Amneal Pharmaceuticals	3.9796 of 5 stars	$17.14 -1.7%	$19.00 +10.9%	+68.6%	$5.48B	$3.12B	34.99	8,500	Positive News Analyst Forecast
DFTX Definium Therapeutics	2.8238 of 5 stars	$38.45 +0.9%	$63.00 +63.8%	+303.0%	$5.17B	N/A	N/A	40	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GHRS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GH Research (GHRS) Competitors

GHRS vs. LNTH, LQDA, AMRX, DFTX, and MANE

How does GH Research compare to Lantheus?

Summary

How does GH Research compare to Liquidia?

Summary

How does GH Research compare to Amneal Pharmaceuticals?

Summary

How does GH Research compare to Definium Therapeutics?

Summary

How does GH Research compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GH Research (GHRS) Competitors

GHRS vs. LNTH, LQDA, AMRX, DFTX, and MANE

How does GH Research compare to Lantheus?

Do analysts prefer GHRS or LNTH?

Does the media refer more to GHRS or LNTH?

Is GHRS or LNTH more profitable?

Do institutionals and insiders believe in GHRS or LNTH?

Which has preferable valuation & earnings, GHRS or LNTH?

Which has more volatility & risk, GHRS or LNTH?

Summary

How does GH Research compare to Liquidia?

Is GHRS or LQDA more profitable?

Which has preferable valuation & earnings, GHRS or LQDA?

Which has more risk & volatility, GHRS or LQDA?

Do analysts prefer GHRS or LQDA?

Do institutionals & insiders hold more shares of GHRS or LQDA?

Does the media favor GHRS or LQDA?

Summary

How does GH Research compare to Amneal Pharmaceuticals?

Do analysts prefer AMRX or GHRS?

Do insiders & institutionals have more ownership in AMRX or GHRS?

Is AMRX or GHRS more profitable?

Which has more volatility & risk, AMRX or GHRS?

Which has better earnings & valuation, AMRX or GHRS?

Does the media prefer AMRX or GHRS?

Summary

How does GH Research compare to Definium Therapeutics?

Which has preferable earnings & valuation, GHRS or DFTX?

Do institutionals and insiders have more ownership in GHRS or DFTX?

Which has more volatility and risk, GHRS or DFTX?

Is GHRS or DFTX more profitable?

Does the media favor GHRS or DFTX?

Do analysts prefer GHRS or DFTX?

Summary

How does GH Research compare to Veradermics?

Does the media refer more to MANE or GHRS?

Do analysts prefer MANE or GHRS?

Which has preferable valuation and earnings, MANE or GHRS?

Is MANE or GHRS more profitable?

Do institutionals & insiders hold more shares of MANE or GHRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools